Structure Therapeutics Inc. (NASDAQ:GPCR) Holdings Decreased by Price T Rowe Associates Inc. MD

Price T Rowe Associates Inc. MD trimmed its position in Structure Therapeutics Inc. (NASDAQ:GPCR) by 33.1% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,394,306 shares of the company’s stock after selling 690,381 shares during the period. Price T Rowe Associates Inc. MD owned approximately 2.44% of Structure Therapeutics worth $37,814,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Capital International Investors increased its position in shares of Structure Therapeutics by 6.8% in the fourth quarter. Capital International Investors now owns 1,619,081 shares of the company’s stock worth $43,909,000 after acquiring an additional 103,059 shares in the last quarter. Rock Springs Capital Management LP increased its stake in shares of Structure Therapeutics by 1.6% during the 4th quarter. Rock Springs Capital Management LP now owns 1,080,963 shares of the company’s stock worth $29,316,000 after purchasing an additional 17,053 shares during the last quarter. Principal Financial Group Inc. lifted its position in shares of Structure Therapeutics by 45.1% in the fourth quarter. Principal Financial Group Inc. now owns 791,134 shares of the company’s stock worth $21,456,000 after buying an additional 245,775 shares during the last quarter. Franklin Resources Inc. boosted its position in Structure Therapeutics by 4.5% during the fourth quarter. Franklin Resources Inc. now owns 738,090 shares of the company’s stock worth $20,017,000 after purchasing an additional 31,984 shares during the period. Finally, American Century Companies Inc. boosted its holdings in shares of Structure Therapeutics by 12.3% during the 4th quarter. American Century Companies Inc. now owns 612,616 shares of the company’s stock worth $16,614,000 after buying an additional 67,325 shares during the period. Institutional investors own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on GPCR. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an “outperform” rating for the company. Stifel Nicolaus assumed coverage on shares of Structure Therapeutics in a report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price objective for the company. Finally, HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Structure Therapeutics in a report on Tuesday, April 22nd. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $81.29.

Structure Therapeutics Stock Up 9.7 %

GPCR stock opened at $25.91 on Wednesday. Structure Therapeutics Inc. has a twelve month low of $13.22 and a twelve month high of $62.74. The company has a market cap of $1.49 billion, a P/E ratio of -35.01 and a beta of -1.35. The business has a fifty day moving average of $20.21 and a 200-day moving average of $27.59.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, February 27th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. As a group, equities research analysts anticipate that Structure Therapeutics Inc. will post -0.82 earnings per share for the current fiscal year.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.